top-banner

NEWS ROOM

Medicover Genetics’ expands its testing portfolio by launching comprehensive pharmacogenomic testing

July 2025 - Medicover Genetics is pleased to announce the launch of Pharmacogenomic Preventive and Diagnostic Testing, comprehensive pharmacogenetics solutions for preventive and personalized prescribing.

Up to 50% of adverse drug reactions (ADRs) may have a genetic cause, and pharmacogenomics (PGx) helps predict how a person’s genes influence their response to medication, impacting both safety and efficacy. PGx testing
enables healthcare providers to identify which medications are likely to be more effective and better tolerated. It can be used preventively, to guide safer and more effective prescribing before treatment begins, or diagnostically, to optimize medications when patients experience side effects, poor efficacy, or treatment failure.

Our tests:

PGx Preventive Panel
A broad, preemptive screening test that analyzes 25 clinical relevance genes across multiple therapeutic areas to support safer, more personalized prescribing before treatment begins. It is applicable across multiple specialties, including internal medicine, cardiology, psychiatry and geriatrics.

PGx Diagnostic Testing

Targeted tests to support therapy decisions in patients with a clinical indication or already undergoing treatment. ​It includes clinically validated gene panels and single-gene analyses tailored to relevant clinical specialties such as psychiatry, oncology, cardiology, and pain management to support therapy selection, dose optimization, and reduce the risk of adverse drug reactions.

PGx diagnostic testing includes
• PGx panels by clinical area to support therapy selection and dose optimization
• PGx guideline-based tests that follow recommendations from leading pharmacogenetic organizations and support safe and effective prescribing
• PGx oncology tests to personalize cancer therapy, reduce toxicity risk, and support safer treatment decisions

Pharmacogenomics is transforming the way physicians prescribe, enabling personalized, safer, and more effective treatment plans. With the launch of this comprehensive PGx portfolio, Medicover Genetics is equipping clinicians with actionable, evidence-based insights that can enhance patient outcomes across many specialties.

For more details, visit our Pharmacogenomics page.

OUR NETWORK